{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["116(4)"],"submitter":["Philippe A"],"funding":["Agence Nationale de la Recherche","Fondation de France"],"pubmed_abstract":["<h4>Background</h4>Coronavirus disease 2019 (COVID-19) is associated with an inflammatory cytokine burst and a prothrombotic coagulopathy. Platelets may contribute to microthrombosis, and constitute a therapeutic target in COVID-19 therapy.<h4>Aim</h4>To assess if platelet activation influences mortality in COVID-19.<h4>Methods</h4>We explored two cohorts of patients with COVID-19. Cohort A included 208 ambulatory and hospitalized patients with varying clinical severities and non-COVID patients as controls, in whom plasma concentrations of the soluble platelet activation biomarkers CD40 ligand (sCD40L) and P-selectin (sP-sel) were quantified within the first 48hours following hospitalization. Cohort B was a multicentre cohort of 2878 patients initially admitted to a medical ward. In both c"],"journal":["Archives of cardiovascular diseases"],"pagination":["183-191"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9925415"],"repository":["biostudies-literature"],"pubmed_title":["Platelet activation and coronavirus disease 2019 mortality: Insights from coagulopathy, antiplatelet therapy and inflammation."],"pmcid":["PMC9925415"],"pubmed_authors":["Sanchez O","Fauvel C","Planquette B","Mirault T","Smadja DM","Weizman O","Chocron R","Samama CM","Philippe A","Waldmann V","Cohen A","Gaussem P","Hadjadj J","Guerin CL","Gendron N","Terrier B","Bonnet G","Hauw-Berlemont C","Fontenay M","Sutter W","Yatim N","Diehl JL"],"additional_accession":[]},"is_claimable":false,"name":"Platelet activation and coronavirus disease 2019 mortality: Insights from coagulopathy, antiplatelet therapy and inflammation.","description":"<h4>Background</h4>Coronavirus disease 2019 (COVID-19) is associated with an inflammatory cytokine burst and a prothrombotic coagulopathy. Platelets may contribute to microthrombosis, and constitute a therapeutic target in COVID-19 therapy.<h4>Aim</h4>To assess if platelet activation influences mortality in COVID-19.<h4>Methods</h4>We explored two cohorts of patients with COVID-19. Cohort A included 208 ambulatory and hospitalized patients with varying clinical severities and non-COVID patients as controls, in whom plasma concentrations of the soluble platelet activation biomarkers CD40 ligand (sCD40L) and P-selectin (sP-sel) were quantified within the first 48hours following hospitalization. Cohort B was a multicentre cohort of 2878 patients initially admitted to a medical ward. In both c","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2025-04-05T11:43:37.792Z","creation":"2025-02-18T22:34:12.25Z"},"accession":"S-EPMC9925415","cross_references":{"pubmed":["36858909"],"doi":["10.1016/j.acvd.2023.01.006"]}}